Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials.

"COMPETING INTERESTS M.P. has received partnership funding for the following: MRC Clinical Pharmacology Training Scheme (co‐funded by MRC and Roche, UCB, Eli Lilly and Novartis); a PhD studentship jointly funded by EPSRC and Astra Zeneca; and grant funding from Vistagen Therapeutics. He has also unrestricted educational grant support for the UK Pharmacogenetics and Stratified Medicine Network from Bristol‐Myers Squibb and UCB. He has developed an HLA genotyping panel with MC Diagnostics, but does not benefit financially from this. He is part of the IMI Consortium ARDAT (www.ardat.org). None of these of funding sources have been used for the current paper. None of the other authors declared any competing financial interests."

"I.G.A. thanks the University of Liverpool for studentship funding support. University of Liverpool."

"We followed a predefined protocol (PROSPERO: CRD42020191283) as previously reported. This manuscript follows the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines (Table )."